Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Autologous Cell Therapy Product Market to Reach USD 35.64 Billion By 2027 | Reports And Data

This image opens in the lightbox

News provided by

Reports And Data

23 Jul, 2020, 14:00 GMT

Share this article

Share toX

Share this article

Share toX

- The growing demand to treat autoimmune diseases and advancement in technology is fostering market growth

- Market Size – USD 9.29 Billion in 2019, Market Growth - CAGR of 17.7%, Market Trends – Rise in cardiovascular incidences

NEW YORK, July 23, 2020 /PRNewswire/ -- The global Autologous Cell Therapy Product Market is forecast to reach USD 35.64 billion by 2027, according to a new report by Reports and Data. The primary factor driving the market is the growing incidence of chronic diseases such as cancer, autoimmune diseases, and blood cancer, among many others. The rise in the population suffering from chronic conditions is also augmenting the market growth.

The global autologous cell therapy product market is anticipated to showcase an intensely competitive atmosphere in the following years. The principal performers in the market cooperate in joint investments, takeovers, mergers, and benefits to gain entry into the national market. Corporations are also setting up manufacturing units and subsidiaries in developing nations, and this initiative is contributing to the high demand for the market.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/3355

The inception of effective guidelines for cell therapy manufacturing, the development of advanced genomic analysis techniques, a vast amount of research by cancer societies, and proven effectiveness of transplants are some of the primary growth drivers for the autologous cell therapy product market. Certain pharmacological and manufacturing issues and regulatory hurdles are restricting the growth of the market. The Japanese government has recognized autologous cell therapy and regenerative medicine as a major donor to the country's economic growth. This has attracted the attention of global market players towards the Asian market, thereby fostering marketing operations in the region.

The COVID-19 impact:

The market for autologous cell therapy products will witness a surge in demand as biopharmaceutical innovators are in the front line for the human response to the global COVID-19 pandemic. A remarkable number of biotech firms are in the midst of a race to scrutinize the virus's genome and are trying to develop a viable vaccine. These companies are investigating the virus at an unparalleled rate, and considerable funds are being invested in the research. The companies have entered the trial stage, and the private and public sectors are working continuously for the development of the vaccine.

To identify the key trends in the industry, click on the link below: 

https://www.reportsanddata.com/report-detail/autologous-cell-therapy-product-market

Further key findings from the report suggest

  • The global autologous cell therapy market is expected to grow at a significant CAGR over 2019 to 2027 due to the increasing predominance of cancer across the globe, rising investments from the government and market performers receiving support for the products.
  • Based on application, the cancer segment accounted for most extensive market income share in 2019, owing to the rise in the number of patients suffering from this disease.
  • According to the World Health Organization, there were 18.1 million new cases of cancer in 2018 and 9.6 million deaths in the same year. The cancer research UK has stated that the population suffering from cancer is expected to grow in the future. It is predicted that there will be 27.5 million new cases each year globally by the year 2040.
  • The hospital emerged as the largest end-user segment and is estimated to generate revenue of over USD 14.26 billion by 2027. The lucrative growth in the segment is due to the increase in the number of pipeline projects over the past few years. As per the Cancer Research Institute (CRI), the number of projects rose from 753 in 2018 to 1,011 in 2019.
  • North America is expected to be an active region autologous cell therapy product market over the forecast period. The United States will be the major contributor and the market is expected to witness high growth here owing to the huge amount of funding by the government and private firms for clinical trials. The region is expected to exhibit a CAGR of 18.2% over the forecast period.
  • Key participants include Brainstorm Cell Therapeutics Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Holostem Terapie Avanzate Srl, FUJIFILM Holdings Corp., Teva Pharmaceutical Industries Ltd, Osiris Therapeutics Inc., Sumitomo Chemical Co. Ltd., Takeda Pharmaceutical Co. Ltd, and Vericel Corp among others.

Order Now: https://www.reportsanddata.com/checkout-form/3355

For the purpose of this report, Reports and Data have segmented into the global autologous cell therapy product market on the basis of source, end-user, application, and region:

Source Outlook (Revenue, USD Billion; 2017-2027)

  • Bone Marrow
  • Epidermis

End-User Outlook (Revenue, USD Million; 2017-2027)

  • Hospitals
  • Ambulatory Centers
  • Research Centers

Application Outlook (Revenue, USD Billion; 2017-2027)

  • Cancer
  • Neurodegenerative Diseases
  • Wound Healing
  • Orthopedic
  • Cardiovascular diseases
  • Autoimmune Diseases

Regional Outlook (Revenue, USD Billion; 2017-2027)

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • U.K
    • France
    • BENELUX
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • Rest of APAC
  • MEA
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • Latin America
    • Brazil
    • Rest of LATAM

Browse more similar reports on Pharma and Healthcare category by Reports And Data

  • Oncology Nutrition Market: https://www.reportsanddata.com/report-detail/oncology-nutrition-market
  • 4D Printing in Healthcare Market: https://www.reportsanddata.com/report-detail/4d-printing-in-healthcare-market
  • Dry Mouth Relief Market: https://www.reportsanddata.com/report-detail/dry-mouth-relief-market

About Reports and Data 

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs 

Logo: https://mma.prnewswire.com/media/1009077/Reports_And_Data_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.